Rudolph M Navari1,2, Lawrence H Einhorn3,4, Patrick J Loehrer3,4, Steven D Passik5, Jake Vinson6, John McClean7, Naveed Chowhan8, Nasser H Hanna3,4, Cynthia S Johnson9. 1. Notre Dame Cancer Institute, University of Notre Dame, 224 Raclin-Carmichael Hall, Notre Dame, IN 46556, USA. Navari.1@nd.edu. 2. Indiana University School of Medicine South Bend, South Bend, IN, USA. Navari.1@nd.edu. 3. Division of Hematology-Oncology, Indiana University Medical Center, Indianapolis, IN, USA. 4. Indiana University Cancer Center, Indianapolis, IN, USA. 5. Memorial Sloan-Kettering Cancer Center, New York, NY, USA. 6. Hoosier Oncology Group, Indianapolis, IN, USA. 7. Medical and Surgical Specialists, Galesburg, IL, USA. 8. Cancer Care Center, New Albany, IN, USA. 9. Division of Biostatistics, Indiana University School of Medicine, Indianapolis, IN, USA.
Abstract
OBJECTIVE: The purpose of this study is to determine the control of acute and delayed chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic chemotherapy (MEC) and highly emetogenic chemotherapy (HEC) with the combined use of palonosetron and olanzapine, and dexamethasone with the dexamethasone given on day 1 only. MATERIALS AND METHODS: Forty chemotherapy-naive patients received on the day of chemotherapy, day 1, an anti-emetic regimen consisting of dexamethasone, palonosetron, and olanzapine. Patients continued olanzapine for days 2-4 after chemotherapy administration. Patients recorded daily episodes of emesis, daily symptoms utilizing the M.D. Anderson Symptom Inventory, and the utilization of rescue therapy. RESULTS: For the first cycle of chemotherapy, the complete response (no emesis, no rescue) for the acute period (24 h post-chemotherapy) was 100%, the delayed period (days 2-5 post-chemotherapy) 75%, and the overall period (0 120 h post-chemotherapy) 75% in 8 patients receiving HEC and was 97, 75, and 72% in 32 patients receiving MEC. Patients with no nausea for the acute period was 100%, the delayed period 50%, and the overall period 50% in 8 patients receiving HEC and was 100, 78, and 78% in 32 patients receiving MEC. DISCUSSION: The complete response and control of nausea in subsequent cycles of chemotherapy were not significantly different from cycle one. CONCLUSION: Olanzapine combined with a single dose of dexamethasone and a single dose of palonosetron was very effective in controlling acute and delayed CINV in patients receiving both HEC and MEC.
OBJECTIVE: The purpose of this study is to determine the control of acute and delayed chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic chemotherapy (MEC) and highly emetogenic chemotherapy (HEC) with the combined use of palonosetron and olanzapine, and dexamethasone with the dexamethasone given on day 1 only. MATERIALS AND METHODS: Forty chemotherapy-naive patients received on the day of chemotherapy, day 1, an anti-emetic regimen consisting of dexamethasone, palonosetron, and olanzapine. Patients continued olanzapine for days 2-4 after chemotherapy administration. Patients recorded daily episodes of emesis, daily symptoms utilizing the M.D. Anderson Symptom Inventory, and the utilization of rescue therapy. RESULTS: For the first cycle of chemotherapy, the complete response (no emesis, no rescue) for the acute period (24 h post-chemotherapy) was 100%, the delayed period (days 2-5 post-chemotherapy) 75%, and the overall period (0 120 h post-chemotherapy) 75% in 8 patients receiving HEC and was 97, 75, and 72% in 32 patients receiving MEC. Patients with no nausea for the acute period was 100%, the delayed period 50%, and the overall period 50% in 8 patients receiving HEC and was 100, 78, and 78% in 32 patients receiving MEC. DISCUSSION: The complete response and control of nausea in subsequent cycles of chemotherapy were not significantly different from cycle one. CONCLUSION:Olanzapine combined with a single dose of dexamethasone and a single dose of palonosetron was very effective in controlling acute and delayed CINV in patients receiving both HEC and MEC.
Authors: F P Bymaster; J F Falcone; D Bauzon; J S Kennedy; K Schenck; N W DeLapp; M L Cohen Journal: Eur J Pharmacol Date: 2001-11-02 Impact factor: 4.432
Authors: Paul J Hesketh; Steven M Grunberg; Richard J Gralla; David G Warr; Fausto Roila; Ronald de Wit; Sant P Chawla; Alexandra D Carides; Juliana Ianus; Mary E Elmer; Judith K Evans; Klaus Beck; Scott Reines; Kevin J Horgan Journal: J Clin Oncol Date: 2003-10-14 Impact factor: 44.544
Authors: R Gralla; M Lichinitser; S Van Der Vegt; H Sleeboom; J Mezger; C Peschel; G Tonini; R Labianca; A Macciocchi; M Aapro Journal: Ann Oncol Date: 2003-10 Impact factor: 32.976
Authors: R M Navari; R R Reinhardt; R J Gralla; M G Kris; P J Hesketh; A Khojasteh; H Kindler; T H Grote; K Pendergrass; S M Grunberg; A D Carides; B J Gertz Journal: N Engl J Med Date: 1999-01-21 Impact factor: 91.245
Authors: Thaiana Aragão Santana; Damila Cristina Trufelli; Leandro Luongo de Matos; Felipe Melo Cruz; Auro Del Giglio Journal: Support Care Cancer Date: 2014-08-22 Impact factor: 3.603
Authors: Michelle C Janelsins; Mohamedtaki A Tejani; Charles Kamen; Anita R Peoples; Karen M Mustian; Gary R Morrow Journal: Expert Opin Pharmacother Date: 2013-04 Impact factor: 3.889